Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRAF Antikörper:
anti-Rat (Rattus) BRAF Antikörper:
anti-Mouse (Murine) BRAF Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal BRAF Primary Antibody für FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Polyclonal BRAF Primary Antibody für DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
Human Monoclonal BRAF Primary Antibody für ELISA, ICC - ABIN2869395
Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. in Endocrine-related cancer 2006
Show all 3 Pubmed References
Human Polyclonal BRAF Primary Antibody für ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
Human Monoclonal BRAF Primary Antibody für PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
BRAF V600E mutation is associated with increased risk of skin metastases in chemo-resistant metastatic colorectal cancer.
BRAF(V600E) gain-of-function mutation has been reported in over 50% of Erdheim-Chester disease patients.
results confirm that BRAF V600E-positive hairy cell leukemia is a relatively rare disorder in the Japanese leukemia patient population.
BRAF and EGFR (zeige EGFR Antikörper) inhibitors are able to synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells
A diligent morphological examination to look for the presence of hairy cells along with flow cytometric immunophenotyping showing consistent bright expression of CD200 (zeige CD200 Antikörper), in addition to well-described characteristic immunophenotype, helps in correctly diagnosing the case. This can be further confirmed by the consistent presence of V600E point mutation in BRAF gene.
BRAF mutations are associated with colorectal liver metastases.
Multivariate analyses revealed that the PIK3CA (zeige PIK3CA Antikörper) mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA (zeige PIK3CA Antikörper) mutations were significantly associated with APC (zeige APC Antikörper) alterations (p = 0.0007) and BRAF mutations (p = 0.0090).
The present findings suggested that miR9 may suppress the viability ofpapillary thyroid carcinoma (PTC (zeige F9 Antikörper)) cells and inhibit tumor growth through directly targeting the expression of BRAF in PTC (zeige F9 Antikörper).
MET inactivation in the context of the BRAF-activating mutation is driven through a negative feedback loop involving inactivation of PP2A (zeige PPP2R4 Antikörper) phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985.
Data show that glycogen synthase kinase 3 (GSK3) and proto-oncogene (zeige RAB1A Antikörper) proteins B-raf (BRAF)/MAPK (zeige MAPK1 Antikörper) signaling converges to control microphthalmia-associated transcription factor MITF (MITF (zeige MITF Antikörper)) nuclear export.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (zeige TWIST2 Antikörper) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (zeige CDX2 Antikörper) silencing to alter gene expression. Like human serrated lesions, CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (zeige SLITRK1 Antikörper) reduces copper levels and MAPK (zeige MAPK1 Antikörper) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (zeige ROCK2 Antikörper) form independent RAF1 (zeige RAF1 Antikörper) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (zeige EGF Antikörper)).
Braf(V600E) expression, coupled with simultaneous p53 (zeige TP53 Antikörper) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (zeige RAF1 Antikörper) operate independently to balance MAPK (zeige MAPK1 Antikörper) signaling: BRAF promotes ERK (zeige EPHB2 Antikörper) activation, while RAF1 (zeige RAF1 Antikörper) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (zeige PAX3 Antikörper).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein